BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating
Esperion Therapeutics shares rise 1.4% after Piper Sandler rates them "overweight" with a $9 price target, citing strong sales potential for its bempedoic acid franchise. The brokerage expects U.S. sales to exceed $650 million, supported by broad labels and payer access. Out of 8 analysts, 6 recommend buying the stock, which is up 44% YTD.
Shares of drug developer Esperion Therapeutics (ESPR.O) gain 1.4% to $3.22 premarket
Piper Sandler initiates with “overweight” rating, sets PT at $9, among the highest on Wall Street
Says company’s bempedoic acid franchise (Nexletol and Nexlizet) for hypercholesterolemia and cardiovascular disease risk well-positioned for sales expansion
A broad label, evolving clinical practice guidelines, and wide payer access are supporting factors; risk/reward profile attractive - Piper Sandler
Brokerage also expects peak U.S. sales to exceed $650 million, complemented by a notable ex-U.S. royalty stream
Out of 8 analysts that cover stock, six rate “strong buy” or “buy”, one rates “hold” and one “sell” - data compiled by LSEG
ESPR stock up about 44% YTD, till last close
